Last Updated : April 27, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort descending | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Keytruda | pembrolizumab | Triple-negative breast cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Orladeyo | berotralstat | hereditary angioedema (HAE) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Opdivo | nivolumab | Urothelial carcinoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Qulipta | atogepant | Migraine, prevention | Reimburse with clinical criteria and/or conditions | Complete | ||
| Tecentriq | atezolizumab | Non-small cell lung cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Zepzelca | lurbinectedin | metastatic small cell lung cancer (SCLC) | Do not reimburse | Complete | ||
| Dayvigo | lemborexant | Insomnia | Do not reimburse | Complete | ||
| Keytruda | pembrolizumab | Renal cell carcinoma, adjuvant | Reimburse with clinical criteria and/or conditions | Complete | ||
| Keytruda and Lenvima | pembrolizumab and lenvatinib | Advanced endometrial cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Gavreto | pralsetinib | RET fusion-positive non-small cell lung cancer | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : April 27, 2024